RecruitingNCT06577779
Jornay PM treatment and daytime ADHD symptoms in adults
About this title
Read the official source — NCT06577779Medication studyAges 18–60United States
Understand this study
Who could participate?
Listed age limits: 18 years to 60 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 29, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 30
- Sponsor
- NYU Langone Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT06577779
- Official title
Show the full official title
An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening
Recruitment & locations
RecruitingNew York
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is NYU Langone Health.
Does this study involve medication?
Yes. The study involves medication, including Methylphenidate Hydrochloride Extended Release Capsule.
Who can participate?
Listed age limits: 18 years to 60 years.
Is this study still recruiting?
The registry lists this study as recruiting.
